#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rhabdoid tumour Cutaneous T-cell lymphoma recurrent Central nervous system lymphoma Malignant neoplasm of choroid Dermatomyositis Oesophageal atresia Alexander disease Angelman's syndrome Acute graft versus host disease in liver Paget's disease of the vulva Renal cancer metastatic Huntington's disease Pulmonary hypertension Polymyositis Hypoxic-ischaemic encephalopathy More trials…

    Learn about Rare Diseases

    Myxofibrosarcoma Factor IX deficiency – Treatment Glycogen storage disease type V – Treatment Osteosarcoma metastatic Glycogen storage disease type I – Diagnostics Wiskott-Aldrich syndrome – Basic Information Glycogen storage disease type V – Trials in Disease Mantle cell lymphoma stage III Mucopolysaccharidosis III – Life with Disease Osteosarcoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fosaprepitant Amifostine Thiol Ab-1002 Valine Milnacipran Hydrochloride Estradiol Hemihydrate Inclisiran Sodium Osteodex Temozolomide Busulfan Pegipanermin Dornase Alfa Inclisiran Sargramostim Cinnarizine Tng462 Asundexian Ibuprofen Sodium Dihydrate Tremelimumab NALOXEGOL More therapies…

    Learn about Your Condition

    Psoriasis Malignant mast cell neoplasm White matter lesion Circulatory collapse Patent ductus arteriosus Lymphocytic lymphoma Metastases to liver Staphylococcal infection Bipolar I disorder Macular oedema Porphyria non-acute Arteriosclerosis Chronic myeloid leukaemia Bacterial infection Breast angiosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

B-cell type acute leukaemia

  • Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • B-cell type acute leukaemia
    • Plasma cell myeloma
    Investigated Drugs:
    • Autologous T-Cells Encoding A Chimeric Antigen Receptor Targeting Human B Cell Maturation Antigen
    • Rapcabtagene Autoleucel
    • Tisagenlecleucel
    Austria Belgium Denmark Finland France Germany +6

  • Study on CD19-CAR T Cells, Fludarabine, and Cyclophosphamide for Children and Young Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Cd19-Car_Lenti_Allo
    • Fludarabine Phosphate
    • Cyclophosphamide
    Italy

  • Comparing human normal immunoglobulin (iv) and a drug combination to prevent infections in adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma treated with CAR-T cells

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Amoxicillin Trihydrate
    • Azithromycin
    • Amoxicillin Sodium
    France

  • A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia recurrent
    • Acute lymphocytic leukaemia
    • B-cell lymphoma recurrent
    Investigated Drugs:
    • MB-HUCART19.1
    The Netherlands

  • Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
    • Tocilizumab
    France Germany Italy Spain

  • Study of UCART22 for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Alemtuzumab
    • Ucart22
    • Fludarabine Phosphate
    France Italy Spain
Previous Page
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!